The U.S. administration is pushing for the onshoring of pharmaceutical production. But is there a sufficient supply of qualified people to staff expanded bioprocessing operations?

To explore that question, we sit down with Eric Langer, the president and managing partner of BioPlan Associates. For more than 20 years, his firm has been publishing the Annual Report of Biopharmaceutical Manufacturing Capacity and Production, so he has the data to back up his views.

We discussed:

• The current state of bioprocessing hiring and long-term trends

• The situation at CDMOs compared to innovator companies

• The impact of geopolitics, including changes to H-1B visa rules

• Job-seekers’ emotional reactions to the current climate

• The staff training gap for expanding manufacturing operations

Eric shares his assessment, putting it all into context—considering both current events and more than 20 years of data.

Learn more & connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Eric Langer: LinkedIn

• Check out the 22nd Annual Report of Biopharmaceutical Manufacturing Capacity and Production

• Connect with our podcast host, Laura Bush: LinkedIn

On August 16, the administration issued an executive order to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The plan begins by stockpiling a six-month supply of 26 critical drugs, with the goal of expanding to a list of 86 essential medicines. What does this mean for pharmaceutical manufacturing, contract development and manufacturing organizations (CDMOs), and the broader drug supply chain?

In this episode of BWS Dialogues, we sit down with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), to unpack the implications of this initiative. Gil shares insights and offers a candid look at the opportunities, challenges, and unintended consequences.

We explore questions such as:

• How does this plan build on—and differ from—previous U.S. drug stockpiling efforts?

• What short- and long-term impacts could this initiative have on pharmaceutical manufacturing and the CDMO sector?

• How effective are other recent measures, like accelerated FDA plant approvals, the PreCheck program, and EQUIP-A-Pharma in supporting U.S.-based drug manufacturing?

• How would pharmaceutical tariffs affect innovators, generics companies, and CDMOs?

• What other factors need to be considered to make reshoring efforts work?

Gil offers his perspectives on how these programs intersect, what gaps remain, and what it will take to build a more resilient pharmaceutical supply chain in the United States.

Learn More & Connect!

• Visit brandwidthsolutions.com for more information about our services!

• Connect with our guest, Gil Roth: LinkedIn

• Connect with our podcast host, Laura Bush: LinkedIn